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Background
The NIH:OVCAR-3 is a cisplatin refractory cell line
established from malignant ascites of a patient with pro-
gressive adenocarcinoma of the ovary after combination
chemotherapy with cyclophosphamide, Adriamycin, and
cisplatin [1]. Thus, OVCAR3 serves as a model cell line
for drug resistance in ovarian cancer. Here, we perform a
comparative transcriptome analysis from the US National
Cancer Institute human tumor cell line anticancer drug
screen (NCI60) dataset [2]. Our results indicate a specific
gene transcription profile of OVCAR3 genes relative to
non-cancerous Human Ovarian Surface Epithelial cells
(HOSE) and drug sensitive Serous Ovarian Cancer
Epithelial Samples (CEPI) and SKOV3 cell lines. Pathway
enrichment analysis from OVCAR3 unique transcripts
was conducted using KEGG; Disease and Drug term
enrichment used the PharmGKB [3] databases.
Materials and methods
Datasets from the NCI60 were obtained from the Gene
Expression Omnibus (GEO) of NCBI [4] (OVCAR3 and
SKOV3 from series GSE2003, OSE and CEPI from series
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Table 1 Transcripts differentially expressed in OVCAR3 versus SKOV3 and CEPI having significant enrichment scores in




ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ENSG00000125257
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha
hydroxysteroid dehydrogenase, type III)
ENSG00000151632
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) ENSG00000076242
GLS glutaminase ENSG00000115419
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) ENSG00000005884
UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6 ENSG00000167165
PPARG peroxisome proliferator-activated receptor gamma ENSG00000132170
NNMT nicotinamide N-methyltransferase ENSG00000166741
PTGIS prostaglandin I2 (prostacyclin) synthase ENSG00000124212
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 ENSG00000108846
UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 ENSG00000241635
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) ENSG00000141736
AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid
dehydrogenase)
ENSG00000187134
FGF2 fibroblast growth factor 2 (basic) ENSG00000138685
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GDS3592 and GSE14407). Transcriptome data analysis
was conducted with Partek Genomics Suite version 6.6.
The WEB-based GEne SeT AnaLysis Toolkit (WebGes-
talt) was used to perform enrichment analysis [5]. Genes
present in KEGG pathway, PharmGKB Disease, and Drug
terms enrichment sets were connected and expanded to
one degree of biological interaction using the Michigan
Molecular Interactions databases plugin [6] and visua-
lized using Cytoscape version 2.8.3 [7].
Results
Transcriptome analysis of OVCAR3 specific gene
expression changes resulted in 160 significant transcripts
with a fold change > ±2 and an ANOVA derived Benja-
mini Hochberg adjusted p-value < 0.001. Enrichment
analysis using a Hypergeometric test identified 189
PharmGKB Disease terms, 90 Drug terms and 31 KEGG
pathways associated with these genes. A union of the
disease, drug and KEGG pathway gene lists yielded 14
common genes for the dataset which were unique to
OVCAR3 cells versus SKOV3 and CEPI (Table 1).
Conclusions
This list of OVCAR3 unique genes, and the resulting
interactions graph (Figure 1) represent potential pathways
of drug resistance associated genes in ovarian cancer.
Notably, ERBB2 (HER2) and FYN are the hub genes of the
interaction network specific for OVCAR3 cell line. Thus,
they may provide valuable insights into the drug resistance
etiology of ovarian cancer. ERBB2 (HER2) has previously
been reported to interact with Estrogen Receptor (ESR2)
in Breast Cancer [8] and FYN has been implicated in Glio-
blastoma and T-cell Lymphomas [9,10]; however their
detailed roles in Ovarian Cancer have only recently been
studied, warranting further investigation [11,12].
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Figure 1 Interaction network of OVCAR3 unique genes. Diamond and rectangle nodes are seed nodes of 14 OVCAR3 unique genes; circular
nodes are 1 degree of biological interactions; rounded rectangular nodes are the highly connected hubs in the network (FYN and ERBB2).
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